Jenburkt Pharmaceuticals Limited (NSE:JENBURPH)

India · Delayed Price · Currency is INR

946.80

-10.40 (-1.09%)

Last updated: Sep 23, 2026, 3:29 PM IST

Jenburkt Pharmaceuticals Financials Overview

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Revenue & Profits

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	1,687	1,687	1,517	1,420	1,367	1,240
Revenue Growth	9.08%	11.24%	6.85%	3.82%	10.30%	13.44%
Gross Profit	1,351	1,350	1,209	1,106	1,029	918.3
Operating Income	396.57	425.06	376.81	307.84	281.88	254.37
Net Income	328.3	347.36	320.61	259.77	246.07	222.97
Earnings Per Share	74.39	78.71	72.65	58.86	53.90	48.58
EPS Growth	1.20%	8.34%	23.42%	9.21%	10.93%	35.12%

Revenue by Geography

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
India	1,422	1,323	1,216	1,109	1,027
Exports	261.2	190.48	200.23	252.58	210.26
Total	1,683	1,514	1,416	1,361	1,237

Cash & Debt

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Investments	473.16	473.16	231.43	739.69	494.84	465.86
Total Debt	24.88	24.88	38.94	-	29.28	67.55
Net Cash (Debt)	448.28	448.28	192.5	739.69	465.57	398.31
Net Cash Growth	132.88%	132.88%	-73.98%	58.88%	16.89%	-15.15%
Net Cash Per Share	101.58	101.57	43.62	167.61	101.97	86.79

Cash Flow & CapEx

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Operating Cash Flow	-	265.22	279.06	81.24	170.52	92.71
Capital Expenditures	-	-137.17	-197.14	-25.54	-21.05	-30.54
Free Cash Flow	-	128.05	81.92	55.7	149.48	62.17
Free Cash Flow Growth	-	56.30%	47.09%	-62.74%	140.43%	-66.05%

Margins

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Gross Margin	80.09%	79.98%	79.68%	77.92%	75.24%	74.07%
Operating Margin	23.50%	25.19%	24.84%	21.68%	20.61%	20.52%
Pretax Margin	25.55%	27.57%	28.96%	24.78%	24.03%	24.09%
Profit Margin	19.46%	20.59%	21.14%	18.30%	17.99%	17.98%
FCF Margin	-	7.59%	5.40%	3.92%	10.93%	5.01%

Dividends

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '26 Sep 24, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Dividend Per Share	20.700	20.700	18.000	15.300	14.400	12.000
Dividend Per Share Growth	0%	15.00%	17.65%	6.25%	20.00%	17.65%

Valuation

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '26 Sep 24, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
PE Ratio	12.88	12.14	13.93	11.71	11.95	11.66
P/FCF Ratio	33.03	32.93	54.50	54.63	19.66	41.83
PS Ratio	2.51	2.50	2.94	2.14	2.15	2.10